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Background: Peginterferon alfa-2a (40 kDa) is currently administered using a prefilled syringe. 
The peginterferon alfa-2a disposable autoinjector is a new safety-engineered device designed 
to facilitate injection and reduce the risk of needlestick injuries. The analysis of two open-label 
Phase I trials evaluated the pharmacokinetics, successful administration, and tolerability of 
peginterferon alfa-2a when using the autoinjector. The studies were performed to support the 
filing and registration of the autoinjector device.
Methods: In trial 1, 50 healthy adult subjects received one 180 µg dose of peginterferon alfa-2a 
via the autoinjector. Serial blood samples were collected predose, up to 336 hours following 
drug administration, and at follow-up (28 ± 3 days post-dosing) for noncompartmental phar-
macokinetic analysis. Trial 2 randomized 60 adult patients with chronic hepatitis C to 180 µg 
peginterferon alfa-2a once weekly by the autoinjector or prefilled syringe for 3 weeks followed 
by the alternative device (prefilled syringe or autoinjector, respectively) for 3 weeks. Patients 
also received ribavirin. Administration by the devices was evaluated under direct observation 
by a study staff member and by patient subjective assessment.
Results: In trial 1, following a single dose of peginterferon alfa-2a, the maximum plasma 
concentration was 16.1 ± 5.3 ng/mL (mean ± standard deviation), and area under the concen-
tration time curve (0–168 hours) was 1996 ± 613 ng ⋅ hour/mL, similar to that reported using 
a vial/syringe or prefilled syringe. In trial 2, few patients showed handling difficulties with 
either device. Generally, patients were observed to be more satisfied and confident, followed 
instructions better, and successfully initiated injection with the autoinjector versus the prefilled 
syringe. Patients reported the autoinjector to be more convenient and easier to use. No pain or 
discomfort was experienced using the autoinjector. The autoinjector safety profile was consistent 
with that known for peginterferon alfa-2a/ribavirin.
Conclusion: These results indicate that peginterferon alfa-2a can be successfully and safely 
delivered via the autoinjector and that the device is easy to handle.
Keywords: peginterferon alfa-2a, disposable autoinjector, hepatitis C, pharmacokinetics, user 
handling
Introduction
Peginterferon alfa-2a (40 kDa) is a polyethylene glycol (peg)-modified form of 
human recombinant interferon alfa-2a. Peginterferon alfa-2a, at a dose of 180 µg 
once weekly, alone or in combination with ribavirin, is indicated for the treatment 
of chronic hepatitis C infection, including in patients with compensated cirrhosis, as 
well as coinfection with human immunodeficiency virus (HIV).1 It is also approved 
for the treatment of chronic hepatitis B infection.2
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The current standard of care for hepatitis C is   peginterferon 
alfa (peginterferon alfa-2a [40 kDa] or peginterferon alfa-2b 
[12 kDa]) plus ribavirin. The two peginterferon drugs have 
different pharmacologic properties and have different 
  formulations and devices for administration.3–6 Peginterferon 
alfa-2a is currently licensed for administration via either a 
vial and syringe or a prefilled syringe.7 Both of these modes 
of injection employ a separate needle covered by a safety 
shield which has to be attached to the syringe; the safety 
shield must be manipulated to appropriate positions prior to 
and after use. There are a number of potential disadvantages 
to using these two devices which can impact on patient 
acceptance of treatment, including increased anxiety among 
patients with a fear of needles, the possibility of recidivism 
in former users of illicit injectable drugs, and the increased 
risk of needlestick injuries in noninfected individuals. It is 
estimated that, every year, one out of every seven health care 
professionals is accidentally injured by a contaminated sharp 
object, most often a needle, and approximately 62%–88% of 
such cases can potentially be prevented by the use of safer 
devices.8 Performing regular self-injections can also be men-
tally and physically stressful for many patients, and concerns 
regarding correct injection technique, pain on   injection, and 
perceived lack of efficacy can be further potential issues 
affecting treatment acceptance.9,10
To address the above issues, a single-use, disposable auto-
injector (prefilled pen) has undergone clinical development 
by the manufacturer of peginterferon alfa-2a (Roche, Basel, 
Switzerland). This device has features that help simplify the 
injection process and may help improve patient satisfaction 
and overcome injection-related issues. Using the autoinjector 
device, peginterferon alfa-2a is administered subcutaneously 
by pressing and releasing a spring-based activation button. 
After completion of the injection, the autoinjector is removed 
from the skin and the needle is automatically covered by the 
needle shield which locks in place. This is designed to limit 
needle exposure, thereby minimizing the risk for needlestick 
injuries, as well as to shield the needle from view and thus 
may reduce anxiety and the risk of recidivism, if applicable, 
among patients.
Disposable autoinjector combination products are 
already currently marketed for several drug products (eg, the 
Epipen® for anaphylaxis, the Rebiject® for multiple sclerosis, 
and the SureClick® for rheumatoid arthritis and anemia). 
Current evidence suggests that patients prefer autoinjector 
devices over manual injection via a prefilled syringe for 
drug administration, and patients have been reported to 
experience less pain with an autoinjector, and to perceive the 
device as easier and more convenient to use than a prefilled 
syringe.11–14 In addition, patient adherence to treatment 
regimens has been shown to be higher among patients using 
autoinjectors compared with a vial and syringe which may be 
based primarily on patient preference.15,16 This in turn may 
be driven by greater convenience, flexibility, and perceived 
clinical efficacy with autoinjector devices.17
Here, the results from two separate Phase I studies 
evaluating the peginterferon alfa-2a autoinjector device 
are presented. These studies were performed to support 
the filing and registration of the autoinjector device, and 
the design of the user handling protocol was reviewed and 
agreed to by the European and US health authorities. The 
first trial characterizes the pharmacokinetics and evaluates 
the safety profile and tolerability of a single 180 µg dose of 
peginterferon alfa-2a when administered via a disposable 
autoinjector in healthy subjects. The second trial evaluates 
and compares the successful administration and tolerability of 
peginterferon alfa-2a using the autoinjector and the prefilled 
syringe in patients with chronic hepatitis C.
Methods
Both studies were conducted in accordance with the princi-
ples of the Declaration of Helsinki or with the laws and regu-
lations of the country in which the research was conducted. 
The studies fully adhered to the principles outlined in the 
current International Council on Harmonisation Guidelines 
for Good Clinical Practice or with local law if it afforded 
greater protection to the patient. Both study protocols were 
approved by the Institutional Review Board of each partici-
pating institution and written informed consent was obtained 
from all patients prior to any screening assessments.
Trial 1: pharmacokinetic study  
in healthy subjects
Subjects
Subjects (aged 18–65 years, body mass index 18–30 kg/
m2) were assessed as healthy volunteers, after having been 
medically examined and clinically tested. Complete blood 
count, blood pressure, heart rate, and electrocardiogram were 
normal, and HIV , hepatitis B and C, and pregnancy screenings 
(for women) were negative. Eligible patients were required to 
be nonsmokers (for at least 3 months prior to dosing), have a 
negative test for drugs of abuse and alcohol prior to dosing, 
and to have not received interferon or peginterferon within 8 
weeks prior to dosing. Female subjects had to be surgically 
sterile or postmenopausal for the past year (amenorrhea for 
at least 12 consecutive months), and male subjects had to be 
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willing to use one effective method of contraception during 
the study and for 90 days after drug administration.
The main exclusion criteria included the following: 
a history of drug or alcohol abuse within the last year; 
a history of significant allergic conditions; hypersensitivity 
to paracetamol; autoimmune, dermatologic, gastrointestinal, 
renal, hepatic, pulmonary, cardiac, hematologic, endocrine, 
neurologic, or clinically significant cardiovascular or cere-
brovascular disease; a history of thyroid disease, severe retin-
opathy or significant psychiatric disease; use, or anticipated 
use, of any medications within 2 weeks or 5 half-lives of 
the drug before dosing; flu or cold-related symptoms within 
the 2 weeks prior to dosing or any self-limited disease, 
such as gastritis; and aspartate aminotransferase or alanine 
aminotransferase values at screening above the upper limit 
of normal.
Study design
The pharmacokinetic study (Trial 1) was an open-label, 
single-center, single-dose study conducted in France, in 
which 50 healthy subjects received one 180 µg/0.5 mL 
dose of peginterferon alfa-2a (Pegasys®, Roche, Basel, 
  Switzerland) administered subcutaneously by investigational 
staff using the disposable autoinjector. Serial blood samples 
were collected predose, up to 336 hours following drug 
administration, and at follow-up (29 ± 3 days after dosing) 
for noncompartmental pharmacokinetic analysis.
Assessments
The primary objective of this trial was to characterize the 
pharmacokinetics of a single 180 µg dose of peginterferon 
alfa-2a when administered via an autoinjector. The secondary 
objective was to evaluate the safety profile and tolerability 
of peginterferon alfa-2a in healthy subjects. The pharma-
cokinetic parameters evaluated for each subject following 
peginterferon alfa-2a autoinjector administration were: 
observed maximum serum concentration (Cmax); time to Cmax 
(Tmax); area under the concentration-time curve (AUC) from 
time zero to the last measurable concentration (AUC0–last) 
and AUC from time zero extrapolated to infinity (AUC0–∞); 
terminal elimination half-life (t½); apparent volume of 
distribution (Vz/F); and apparent total body clearance (Cl/F). 
Pharmacokinetic parameters were evaluated relative to expo-
sure observed in historic studies (18–20 and data on file). 
Given that many historic studies have had only a single-dose 
pharmacokinetic sample collection up to 168 hours post-dose, 
the AUC from time zero to 168 hours postdose (AUC0–168 h) 
was also estimated for this study.
Serum concentrations of peginterferon alfa-2a were 
  measured using a validated quantitative sandwich enzyme-
linked immunosorbent assay method (range 250–4000 pg/mL). 
The intra-assay precision and accuracy of the quality control 
samples were 2.5%–8.5% and −5.5%–13.2%, respectively. 
The interassay precision of the quality control samples 
were 0.4%–9.0% and 11.7%–16.6%, respectively. Serum 
concentration of anti-peginterferon alfa-2a antibodies was 
measured by a validated quantitative bridging enzyme-linked 
immunosorbent assay (assay range 20–1000 ng/mL). The 
intra-assay precision and accuracy of the quality control 
samples were 1.3%–3.6% and −3.2%–6.0%, respectively. 
The interassay precision and accuracy of the quality control 
samples were 3.9%–4.9% and 4.9%–9.0%, respectively. 
The safety profile and tolerability were assessed throughout 
the study by monitoring vital signs, laboratory safety tests, 
electrocardiogram, and adverse events.
Trial 2: user-handling study in patients 
with chronic hepatitis C
Subjects
Trial 2 enrolled adult patients (18 years) with chronic hepati-
tis C infection who had never previously used an   autoinjector. 
Patients were either treatment-naïve or treatment-experienced 
(protocol-defined as 12 weeks’ prior experience with 
peginterferon). All patients had to be willing and physically 
able to self-inject the study medication. Females of childbear-
ing potential had a negative urine pregnancy test documented 
within 24 hours prior to the first dose of study drug and had to 
be willing to use two forms of contraception during the study. 
In addition, females of childbearing potential and males with 
female partners of childbearing potential who were receiv-
ing concomitant treatment with ribavirin had to be willing to 
follow the requirements regarding contraception according 
to the locally approved label.
Exclusion criteria included the following: hypersensitivity 
to peginterferon alfa-2a or any of its components; autoimmune 
hepatitis; a history of, or clinical evidence of, decompensated 
liver disease; concomitant treatment requiring administration 
by self-injection; absolute neutrophil count ,1500 cells/mm3; 
platelet count ,90,000 cells/mm3; history of severe   psychiatric 
disease; treatment with any investigational drug 6 weeks 
or five half-lives of the drug prior to the first dose of study 
drug; evidence of serious uncontrolled chronic disease; 
poorly controlled thyroid dysfunction; evidence of an active 
or suspected malignancy or a history of malignancy within 
the previous 2 years where the risk of recurrence was 20%; 
history or evidence of severe retinopathy or clinically 
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  relevant   ophthalmologic disorder; and history of major organ 
  transplantation with an existing functional graft.
Study design
Trial 2 was a two-arm, crossover, open-label, Phase I study20b 
conducted in the US in which 60 adult patients with chronic 
hepatitis C infection were randomized to 180 µg/0.5 mL 
peginterferon alfa-2a once weekly by either the autoinjec-
tor or prefilled syringe for 3 weeks (weeks 1–3) followed 
by the alternative device (prefilled syringe or autoinjector) 
for 3 weeks (weeks 4–6). Oral ribavirin (Copegus®, Roche, 
Basel, Switzerland) was administered according to standard 
of care as per the investigator’s judgment. Randomization was 
centrally controlled; patients were stratified by experience 
with peginterferon therapy (“yes” vs “no”) and randomization 
numbers were generated by Roche or its designee.
Patients self-administered the subcutaneous injection 
under observation by a study site staff member. Prior to treat-
ment, a study site staff member demonstrated how to self-
administer using the assigned device by written   instructions. 
The patient was given the written instructions and allowed 
time to review the instructions and ask questions prior to 
self-injection.
Patients who required dose modifications or interruptions 
to manage toxicities associated with peginterferon alfa-2a 
were discontinued from the study because a decreased dose 
could only be administered using a vial of peginterferon 
alfa-2a and a syringe. The use of supportive therapies to man-
age toxicities associated with peginterferon and ribavirin was 
allowed according to local guidelines and standard of care.
Assessments
The primary objective was to evaluate the successful admin-
istration of peginterferon alfa-2a using the autoinjector. 
Secondary objectives included assessment of tolerability in 
association with the use of the autoinjector and comparison of 
the ease of handing an autoinjector versus a prefilled syringe. 
Data were recorded via an electronic data capture system 
using electronic case report forms. The safety profile and tol-
erability were assessed by monitoring vital signs, laboratory 
safety tests, electrocardiogram, and adverse events. Since 
there was no validated instrument to evaluate patient-reported 
outcomes using the disposable autoinjector and prefilled 
syringe injection devices, assessment of the injection (suc-
cessful administration and ease of handling) performed by 
the patient was made upon direct observation by a study site 
staff member. In addition, a free-text subjective assessment 
by the patient was collected after each injection.
injection-method observational survey
A member of the site study staff observed patient self-
  administration of the study drug and evaluated their ability 
to follow the instructions for each injection method, handle 
the device, and successfully administer each injection. 
  Observations were recorded based on nine predefined ques-
tions, using a “yes” or “no” response (Table 1A).
Patient subjective assessment of injection method
Prior to completion of the patient subjective assessment of 
the injection method, the injection-method observational 
survey was completed to avoid any influence of the patient’s 
assessment on the staff member’s observations. The patient 
subjective assessment consisted of seven predefined questions 
(Table 1B) and was collected by the study site staff member 
after each injection.
Statistical analyses
Both studies were exploratory in nature and therefore no 
formal statistical comparisons were performed or   appropriate. 
Descriptive analyses describing the results were planned, 
agreed by health authorities for the user handling study, and 
performed per protocol. Formal statistical comparisons were 
not planned and not performed.
Table 1 Questions for the (A) injection-method observational 
survey and (B) subjective patient assessment of injection method
A Injection method observational survey*
Did the patient…
1. Exhibit any nervousness prior to the injection?
2. Exhibit any difficulty initiating the injection?
3. Appear confident performing the injection?
4.   Follow the instructions for performing the injection without the need 
for additional instructions or guidance?
5.   Experience any technical problems with the device or syringe during 
the injection?
6.   Withdraw the device/syringe before the injection was complete, 
as evidenced by withdrawal before the second audible click for the 
autoinjector, and remaining fluid in the barrel for the prefilled syringe?
7.   Exhibit any visible pain or physical discomfort (eg, hand discomfort, 
pain upon injection) during the injection?
8. Appear to be satisfied using the device or syringe?
9. Exhibit any frustration using the syringe or device?
B Patient subjective assessment of injection method
1.   Did you have any concerns about using the device before starting  
the injection?
2. how comfortable were you using the device?
3. Were the instructions easy to follow?
4. Were there any problems with the device itself?
5. Were there any problems performing the injection?
6. Did you experience any pain or discomfort?
7. is there anything else you would like to add?
Note: *Answers recorded as “yes” or “no”.
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In trial 1, peginterferon alfa-2a pharmacokinetic and 
tolerability data were interpreted in the context of historic 
peginterferon alfa-2a data from previous clinical studies 
(8–10 and data on file). A sample size of 50 healthy volun-
teers was deemed appropriate in support of the autoinjector. 
Since no statistical comparisons were planned, sample size 
was not determined by power calculation. All subjects who 
had received the study medication, whether prematurely 
withdrawn from the study or not, were included in the 
safety analysis. Subjects were excluded from the pharma-
cokinetic analysis population if they significantly violated 
the inclusion or exclusion criteria, deviated significantly 
from the protocol, or if data were unavailable or incom-
plete, which might have influenced the pharmacokinetic 
analysis.
For trial 2, a sample size of 60 patients was deemed 
  sufficient in support of the autoinjector. As for trial 1, no 
  formal statistical comparisons were planned, and none 
were performed. Results are summarized using   descriptive 
statistics at scheduled visits. Analyses of data from 
the   injection-method observational survey and patient subjec-
tive assessment of injection method survey were performed 
using an intent-to-treat population, which included all 
patients who received at least one injection and a survey after 
injection. The safety analysis population included all patients 
who received at least one dose of treatment.
Results
Trial 1
Baseline characteristics
All 50 healthy subjects, enrolled at one French investiga-
tion center (Institut de Pharmacologie Clinique Roche in 
Strasbourg), completed trial 1. The majority of subjects were 
Caucasian, male, of mean age 39 years, and had a mean body 
Table 2 Demographic data for trials 1 and 2
Trial 1 
(healthy subjects)  
n = 50
Trial 2 (chronic hepatitis C patients)
AI weeks 1–3; PFS weeks 4–6 
n = 30
PFS weeks 1–3; AI weeks 4–6 
n = 30
Male, n (%) 47 (94) 17 (57) 14 (47)
Mean age, years (range) 39.0 (13.6) 47.6 (23–74) 51.3 (27–69)
Race, n (%)
  White caucasian 47 (94) 26 (87) 28 (93)
  Black/African 2 (4) 4 (13) 2 (7)
  Asian 1 (2) 0 0
hispanic/latino ethnicity, n (%) N/A 7 (23) 4 (13)
Mean body weight, kg (SD) 77.1 (9.9) 88.1 (23.2) 83.4 (17.4)
Mean BMi, kg/m2 (SD) 24.6 (2.7) 31.0 (8.4) 28.9 (5.2)
Note: For trial 2, patient demographic data are presented according to which device they were randomized to first.
Abbreviations: BMI, body mass index; N/A, not assessed; SD, standard deviation; AI, autoinjector; PFS, prefilled syringe.
mass index of 24.6 kg/m2 (Table 2). Enrollment began on 
February 8, 2010 and the study ended on April 16, 2010. 
Five subjects were not considered evaluable for the pharma-
cokinetic assessment due to serum levels of peginterferon 
alfa-2a that were below the limit of quantification of the assay 
for most, or all, of the samples collected. This phenomenon 
has been observed in several previous peginterferon alfa-2a 
pharmacokinetic studies and is considered to be related to 
endogenous substances present in the serum that interfere 
with the ability of the enzyme-linked immunosorbent assay 
to detect peginterferon alfa-2a. Thus, 45 subjects were eli-
gible for pharmacokinetic analysis. All 50 subjects received 
one dose of study treatment and were included in the safety 
analysis population.
Pharmacokinetic analysis
Following a single 180 µg dose administered via the dis-
posable autoinjector, mean peginterferon alfa-2a serum 
concentrations peaked at around 48–96 hours postdose. 
Serum peginterferon alfa-2a concentrations were sustained 
for up to 168 hours (ie, 1 week, Figure 1). The shape of this 
concentration-time profile suggests sustained absorption 
and slow elimination, typical of that observed following 
subcutaneous administration of peginterferon alfa-2a.18,21–23 
Single-dose pharmacokinetic parameters of peginterferon 
alfa-2a after administration via the disposable autoinjector 
are presented in Table 3. Mean peginterferon alfa-2a Cmax, 
AUC0–168 h, and Tmax were similar to those reported in previ-
ous healthy volunteer and patient studies (Figure 2, Table 3) 
following subcutaneous administration via a vial/syringe or 
prefilled syringe. Intersubject variability was approximately 
30% for these parameters, and appeared lower than that 
reported in historic studies (median percent coefficient of 
variation [%CV] 45%; data on file).
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Figure 1 Mean (± standard deviation) peginterferon alfa-2a concentration-time profile after single dose administered via the disposable autoinjector on linear (A) and log 
(B) scales.
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Tolerability
Forty-three of 50 subjects (86%) reported at least one adverse 
event; the 43 subjects experienced a total of 81 adverse 
events. The most common adverse events reported were 
influenza-like illness (40%), headache (34%), myalgia 
(24%), injection site erythema (12%), and pyrexia (10%); 
most adverse events were mild or moderate in intensity 
(80/81 events) and were judged by the investigator as being 
related to study medication (75/81). No serious adverse 
events or deaths occurred during the trial, and no significant 
electrocardiographic abnormalities were reported. No subject 
withdrew prematurely due to an adverse event or laboratory 
abnormalities.
Thirty subjects had a total of 109 laboratory abnormalities, 
the majority of which were decreased neutrophils and white 
blood cell count (n = 25 and n = 15, respectively); none were 
considered clinically significant by the investigator. Two sub-
jects (4%) tested positive for binding antibodies to peginter-
feron alfa-2a at follow-up after administration of peginterferon 
alfa-2a via the disposable autoinjector, similar to that described 
in the package insert for peginterferon alfa-2a (9%–29%).24
Trial 2
Baseline characteristics
In trial 2, 60 patients were enrolled at ten centers in the United 
States (treatment-experienced, n = 29; treatment-naïve, n = 31). 
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Enrollment began in March 2010 and the study ended in May 
2010. Fifty-seven patients completed the study. The three with-
drawals occurred during the autoinjector period and were due 
to adverse events or laboratory abnormalities. All 60 patients 
received treatment via the autoinjector and 59 received treat-
ment via the prefilled syringe; one patient, who received the 
autoinjector first, discontinued during this phase and thus did 
not receive the prefilled syringe. Therefore, the safety analysis 
includes 60 patients for the autoinjector period and 59 for the 
prefilled syringe period. Survey data from all 60 patients are 
included in the survey analyses.
The majority of patients were Caucasian, with a mean 
age of 49 years and a mean body mass index of 30 kg/m2. 
Overall, there were no major differences between patients 
randomized to the disposable autoinjector first, followed 
by prefilled syringe and patients randomized to the pre-
filled syringe first followed by autoinjector (Table 2). 
Baseline characteristics were also similar between treatment-
naïve and treatment-experienced patients (data not shown). 
Almost all patients were receiving concomitant medica-
tions at the start of the study as was expected for a hepatitis 
C-infected population.
injection-method observational survey 
results
Results of the injection-method observational survey are 
summarized for each injection (1, 2, or 3) by injection method 
used (disposable autoinjector or prefilled syringe), regardless 
of timing (weeks 1–3 vs weeks 4–6, Table 4). Overall, few 
patients were observed to have handling difficulties with 
either device. For both devices, more user-handling issues 
tended to be reported by the observer during the first injec-
tion than during the second or third injection; this included 
issues related to the user’s mental state, such as nervousness 
Table 3 Single-dose pharmacokinetic parameters of peginterferon alfa-2a after administration via disposable autoinjector compared 
with historic studies
Parameter (units) N Mean ± SD %CV Historic studies
Healthy volunteer studies* Hepatitis C patient studies†
Mean, range %CV, range Mean, range %CV, range
Tmax (hours) 45 78.7 ± 43.7 55.5 78.0–102 28.0–48.0 57.0–105.0 35.0–70.2
Cmax (ng/mL) 45 16.1 ± 5.3 33.1 9.0–14.2 17.6–38.8 8.0–15.4 26.7–62.4
AUC0–168 h (ng ⋅ hour/mL) 45 1996 ± 613 30.7 950–1743 26.3–50.2 1009–1820 32.2–79.3
AUC0–last (ng ⋅ hour/mL) 45 2736 ± 1054 38.5
AUC0–∞ (ng ⋅ hour/mL) 43 3048 ± 1062 34.9
t1/2 (hours) 43 67.8 ± 36.3 53.5
Vz/F (L) 43 5.9 ± 2.9 49.5
Cl/F (mL/hour) 43 67.5 ± 27.1 40.1
Notes: *NP15537, NP15762, NP15989, NP15580, NP15538; †NV15489, NV15495, NV15496, NV15497, NP17354, and NP17355.
Abbreviations: AUC, area under the concentration-time curve; Cmax, observed maximum serum concentration; Cl/F, apparent total body clearance; Tmax, time to Cmax; 
t½, terminal elimination half-life; Vz/F, apparent volume of distribution; %CV, percent coefficient of variation; AI, autoinjector; PFS, prefilled syringe.
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Figure 2 Mean (± standard deviation) exposure from previous peginterferon alfa-2a healthy volunteer and patient studies.
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and lack of confidence, as well as issues related to operating 
the device, such as difficulty initiating injection, withdrawal 
before injection was complete, and difficulties in using the 
device correctly.
On first injection, slightly more patients using the auto-
injector had technical difficulties with the device (12%; 
prefilled syringe 3%) and withdrew before the injection was 
complete (7%; prefilled syringe 0%). However, user handling 
tended to improve during the second and third injections for 
both devices, and by the third injection, reported difficulties 
were low for both devices.
For the prefilled syringe device, a few patients (2%–10%) 
were identified to have issues with most of the nine criteria in 
the observational survey during the second and third   injections. 
For the disposable autoinjector device, a few patients were 
observed to have technical problems (5%–9%) and difficulty 
following instructions (4%–9%) during the second and third 
injections. However, patients were generally observed to 
be more satisfied, able to follow instructions better, more 
confident, and more able to initiate injection successfully with 
the autoinjector device compared with the prefilled syringe 
device (Table 4). Following first injection, all patients (100%) 
using the autoinjector device and 93%–98% of patients 
using the prefilled syringe successfully initiated injection 
and were confident and satisfied with the respective device. 
Pain/discomfort was not observed in any patients using the 
autoinjector, but a few patients (2%–3%) were observed to 
experience pain/discomfort with the prefilled syringe for each 
of the three injections.
In general, treatment-experienced patients were 
observed to have less difficulty with the first injection 
than treatment-naive patients, particularly when using 
the prefilled syringe (difficulty initiating injection: 
autoinjector 14% vs 10%; prefilled syringe 4% vs 29%; 
and technical problems 10% vs 13%; prefilled syringe 
0% vs 6%, respectively).   Treatment-experienced patients 
were also observed to be less nervous than treatment-naïve 
patients prior to first injection (autoinjector 9% vs 29%; 
prefilled syringe 7% vs 39%). However, there were no 
differences evident between the two patient groups on 
subsequent injections.
Patient subjective assessment
The patient subjective assessment also reflected a positive 
patient opinion on the autoinjector device, including a high 
comfort level and lack of pain compared with the prefilled 
syringe device (Table 5). All patients reported that the 
instructions were easy to follow for both devices. Twenty-five 
percent of patients reported concern about using the autoin-
jector prior to the first injection (25%) compared with 17% 
using the prefilled syringe. Patient concern was generally 
reported to be due to apprehension and not knowing what to 
expect with a new device; no patients reported concern on 
subsequent injections with the autoinjector, and all patients 
were comfortable using the device.
A few patients (approximately 5/60) reported problems 
with the autoinjector device or performing the injection; 
these included failure to release the thumb immediately 
upon injection and removal of the device before injection 
was complete. Several comments were related to the second 
click that indicates delivery of the full dose, with one patient 
failing to observe a second click and two patients removing 
the device prematurely. These comments reflect the technical 
difficulties, lack of adherence to instructions, and withdrawal 
before completion reported in the observational survey for 
the three injections (Table 4).
Table 4 Summary of injection-method observational survey responses by study staff
n (%) Injection 1 Injection 2 Injection 3
AI 
n = 60
PFS 
n = 59
AI 
n = 58
PFS 
n = 59
AI 
n = 57
PFS 
n = 59
Patients exhibited nervousness prior to injection 11 (18) 14 (24) 0 3 (5) 1 (2) 2 (3)
Patients exhibited difficulty initiating injection 7 (12) 10 (17) 0 2 (3) 0 2 (3)
Patients appeared confident performing the injection 58 (97) 46 (78) 58 (100) 57 (97) 57 (100) 58 (98)
Patients successfully followed instructions 58 (97) 54 (92) 53 (91) 53 (90) 55 (96) 56 (95)
Patients experienced technical difficulties with device 7 (12) 2 (3) 5 (9) 1 (2) 3 (5) 3 (5)
Patients withdrew device before completion of injection 4 (7) 0 1 (2) 0 0 1 (2)
Patients exhibited pain/discomfort on injection 0 2 (3) 0 1 (2) 0 2 (3)
Patients appeared satisfied using device 60 (100) 51 (86) 58 (100) 55 (93) 57 (100) 56 (95)
Patients exhibited frustration with device 1 (2) 2 (3) 0 2 (3) 0 2 (3)
Notes: Results summarized for each injection (1, 2, or 3) by injection method used (disposable Ai or PFS), regardless of timing (weeks 1–3 vs weeks 4–6).
Abbreviations: AI, autoinjector; PFS, prefilled syringe.
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For the final part of the survey, patients were asked to 
provide any further comments. Nearly half of all patients 
indicated a preference for the autoinjector device over the 
prefilled syringe (n = 26; 43%). Reasons for preferring the 
autoinjector included: it was easier, quicker, and safer to use; 
less painful; less bruising at injection site; less preparation 
time; no view of the needle which reduced anxiety; cannot be 
reused; less of a reminder of how the virus was   transmitted. 
Two patients (3%) reported that they felt more confident 
using the prefilled syringe device because by being able to 
see the medication in the syringe they were more certain that 
they had successfully administered the drug. The remaining 
patients (n = 32; 53%) either did not offer further comment 
or did not state a preference of one device over the other.
Tolerability
Overall, both devices were well tolerated, with similar adverse 
events reported, consistent with the known safety profile of 
peginterferon alfa-2a plus ribavirin. The most common 
adverse events (.10%) reported during both the   autoinjector 
and prefilled syringe periods were nausea (13% and 14%, 
respectively) and fatigue (13% and 12%,   respectively). No 
serious adverse events or deaths occurred during this trial. 
Three patients were withdrawn from the study for adverse 
events of pulmonary sarcoidosis and thrombocytopenia and 
a laboratory abnormality of low neutrophil count (due to the 
need of dose modification, as per the protocol).
A slightly higher percentage of patients reported an 
adverse event during the prefilled syringe period (64%) 
versus the autoinjector period (57%) but this difference of 
four patients was not considered to be clinically relevant. 
The majority of adverse events were of mild or moderate 
intensity (96% and 99% events during the autoinjector and 
prefilled syringe periods, respectively) and were judged 
by the investigator to be related to the study medication 
(94% and 98% events during the autoinjector and prefilled 
syringe periods, respectively).
The incidence of individual reported adverse events was 
similar in the autoinjector and prefilled syringe periods with the 
exception of diarrhea (7% and 14%, respectively),   arthralgia 
(10% and 5%, respectively), and insomnia (8% and 3%, 
respectively). However, given the relatively small numbers 
of patients reporting these events, the difference between the 
autoinjector and prefilled syringe was not considered clini-
cally different. Very few injection site reactions were reported 
(six patients during the autoinjector period and three patients 
during the prefilled syringe period).
In general, treatment-experienced patients reported 
adverse events less frequently (55% and 43% for the auto-
injector and prefilled syringe periods, respectively) than 
treatment-naïve patients (58% and 84%, respectively). In 
treatment-naïve patients, adverse event reporting was more 
frequent during the prefilled syringe period (84%) than during 
the autoinjector period (58%), and the most common adverse 
events were general disorders (eg, fatigue, pain, chills, and 
irritability) and injection site reactions. For the treatment-
naive patients and treatment-experienced patients, there were 
no clinically relevant differences between the devices in the 
adverse events reported.
The most common marked laboratory abnormality 
was neutropenia during both the autoinjector and prefilled 
syringe periods (34% and 33%, respectively). Other reported 
marked laboratory abnormalities during both the autoinjec-
tor and prefilled syringe periods included low white blood 
cell count (19% and 16%, respectively), low platelets (9% 
and 5%, respectively), low lymphocyte count (9% and 2%, 
respectively), and low hemoglobin (5% and 5%, respectively). 
The majority of the significant laboratory abnormalities were 
reported in treatment-naïve patients (treatment-naïve vs 
treatment-experienced: neutropenia 39%–45% vs 22%–26%; 
Table 5 Summary of patient subjective assessment of the injection method*
The patient Injection 1 Injection 2 Injection 3
AI 
n = 60
PFS 
n = 59
AI 
n = 59
PFS 
n = 59
AI 
n = 57
PFS 
n = 59
Was concerned about using the device preinjection 15 (25) 10 (17) 0 3 (5) 0 2 (3)
Was comfortable using the device 56 (93) 52 (88) 58 (100) 55 (93) 57 (100) 58 (98)
Found instructions easy to follow 60 (100) 59 (100) 58 (100) 59 (100) 57 (100) 59 (100)
Reported problems with the device 4 (7) 0 1 (2) 2 (3) 0 2 (3)
Reported problems performing injection 3 (5) 1 (2) 4 (7) 0 1 (2) 0
Reported pain or discomfort 2 (3) 8 (14) 0 3 (5) 0 4 (7)
Note: *Results summarized for each injection (1, 2, or 3) by injection method used (disposable Ai or PFS), regardless of timing (weeks 1–3 vs weeks 4–6).
Abbreviations: AI, autoinjector; PFS, prefilled syringe.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
595
Peginterferon alfa-2a autoinjectorPatient Preference and Adherence 2011:5
low white cell count 23%–26% vs 7%–11%; and low platelets 
10%–13% vs 0%–4%).
No study-onset electrocardiogram abnormalities were 
reported, and there was no apparent pattern of clinically 
significant changes in vital signs during this study.
Discussion
Together, the two registration studies presented here 
evaluated a new disposable autoinjector that has undergone 
development for the administration of peginterferon alfa-2a. 
The studies assessed the pharmacokinetics, safety profile, 
tolerability, and ease of administration of peginterferon 
alfa-2a by healthy subjects and patients with chronic 
hepatitis C. Overall, the findings indicate that peginterferon 
alfa-2a can be successfully delivered via this device, and are 
comparable with that using the approved prefilled syringe. 
In addition, patients perceived the autoinjector as easier and 
more convenient to use, and tended to show preference over 
the prefilled syringe.
Importantly, data from the 45 evaluable healthy 
subjects in the pharmacokinetic study demonstrate that 
peginterferon alfa-2a, when administered via the dispos-
able autoinjector, has a mean exposure similar to that 
previously reported using a vial and syringe or a prefilled 
syringe (data on file). The mean AUC0–168h in the present 
study was slightly higher relative to previous studies, but 
drug exposure was within the range of previous studies and 
the difference was not considered to be clinically   relevant. 
Although speculative, the difference in intersubject 
  variability observed may be due to greater inconsisten-
cies in administration techniques associated with manual 
injection, where the user has to control the depth, speed, 
and completeness of injection. In contrast, the disposable 
autoinjector is fully automated, and thus variability in 
injection technique may be decreased.
Data from this present analysis also indicate that patients 
can successfully administer peginterferon alfa-2a using the 
new autoinjector device. Survey results indicate that instruc-
tions for use were easy for patients to follow and that there 
was no evidence of pain or discomfort observed during the 
use of the autoinjector device. In addition, patients generally 
perceived the autoinjector to be more convenient, easier, 
quicker, and simpler to use, and were more satisfied with its 
use than the prefilled syringe. These findings are concordant 
with other similar sized studies that have compared patient 
satisfaction and preference between the autoinjector and 
prefilled syringe devices.11–13 However, two patients did 
express a preference for the prefilled syringe device, with 
the primary reason being that they were more confident that 
they had successfully injected the drug. This finding was used 
to support revision of the patient instructions and training 
programs for use of the autoinjector, to ensure patients are 
trained to know when they have successfully completed their 
injection of the drug.
One obvious advantage with the autoinjector device is 
that the needle is shielded from view and the user does not 
need to manually insert the needle into the skin. This is an 
important benefit for patients with a fear of needles as well 
as for previous intravenous drug users who often express 
fear that treatment for hepatitis C virus will cause them to 
relapse back into substance abuse.25,26 The possession of a 
syringe used for the interferon injections and/or the action of 
drawing up the interferon for the injection may stimulate a 
patient’s desire for drugs.25,26 Therefore, by eliminating both 
of these factors, the autoinjector has the potential to reduce 
the risk of recidivism in substance abusers. This is impor-
tant given that the prevalence rate of hepatitis C infection 
among injection drug users ranges between 40% and 90%, 
depending on geographic location and duration of exposure 
to injection drug use.27
Poor adherence to treatment is a universal issue in the 
management of all chronic conditions and can have serious 
consequences, including reduced efficacy and increased 
health care costs.28–30 In hepatitis C, optimal adherence to 
therapy is critical for a successful treatment outcome.31 
Among patients with hepatitis C genotype 1 infection, 
sustained virologic response rates are significantly greater 
in those who receive at least 80% of the total peginterferon 
and ribavirin dose for more than 80% of the scheduled 
treatment duration compared with patients who fail to 
achieve these adherence criteria (51% vs 34%; P = 0.011).32 
Hughes and Shafran33 confirmed that treatment response is 
not only influenced by hepatitis C genotype and viral load, 
but also by patient-related factors, including   adherence. 
Thus, improving adherence is an important goal in the 
management of hepatitis C. By improving convenience 
and shielding the needle from view, findings from this 
study suggest the autoinjector may have the potential to 
help patients overcome injection-related problems, such 
as pain/discomfort, anxiety, fear of needles, fear of recidi-
vism, and worry over incorrect injection techniques, all of 
which may improve patient adherence to study medication, 
which can subsequently increase the potential to achieve 
viral suppression.
The use of the autoinjector did not raise any new safety 
concerns, and the adverse events reported were consistent 
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with the known safety profile of peginterferon alfa-2a among 
patients with hepatitis C.34–36 The autoinjector itself also 
offers administrational safety features, the primary one being 
lack of needle exposure. This reduces the risk of needlestick 
injury, which is a key benefit for the introduction of autoin-
jector devices. Needlestick injury is an important issue that 
needs to be addressed, given that 2%–4% of acute hepatitis 
C infections that occur annually are reported among health 
care workers.8,37 In the US alone, 69,000 injuries a year could 
be prevented through the use of safer devices.38 Furthermore, 
with the autoinjector, the needle cannot be reused, which 
was viewed as an advantage by some patients because many 
chronic hepatitis C patients are intravenous drug users or 
former users.
The positive findings of these analyses should be 
considered in the context of the study limitations. With 
the pharmacokinetic study, there was no control group 
and thus data were compared with the historic studies 
presented in Figure 2. In addition, while tolerability data 
from this pharmacokinetic study were consistent with 
those reported previously with peginterferon alfa-2a in 
clinical trials,24,35,36 it must be recognized that this was 
a single-dose study and cannot be directly compared 
with the safety profile of a 24–48-week treatment with 
peginterferon alfa-2a.
It was not possible to blind study participants in the 
user handling and tolerability study. It is possible that, for 
treatment-experienced patients who were already satisfied 
and comfortable with their existing administration method, 
changing their injection practice may have resulted in lower 
satisfaction with the autoinjector, particularly considering the 
short duration of the study treatment. In addition, treatment-
naïve patients or patients who have previously discontinued 
treatment due to injection-related issues may have perceived 
a greater benefit in using a new device. Assessment of the 
attitudes of health care practitioners was not included in 
the study; evaluation of their use and preferences would be 
of clinical interest, particularly in terms of ease of training 
patients and patient compliance.
However, despite these limitations, the findings from this 
study provide sufficient evidence to support the use of the 
autoinjector as a delivery option for patients.
Although the management of chronic hepatitis C is 
entering a new era with the recent approval of the protease 
inhibitors, telaprevir and boceprevir,39–42 these agents are 
approved only in combination with peginterferon alfa plus 
ribavirin.43,44 Therefore, delivery devices for peginterferon 
alfa-2a, particularly those that can help simplify treatment 
strategies such as the autoinjector, will continue to be of 
clinical relevance for the foreseeable future.
Conclusion
The results of the analyses reported here indicate that 
peginterferon alfa-2a can be successfully and safely delivered 
using the disposable autoinjector, and the serum exposure 
of a single dose of peginterferon alfa-2a is similar to that 
observed previously using a vial and syringe or prefilled 
syringe. Importantly, patients reported that the instructions 
were easy to follow, the device was easy to handle, and there 
were no reported issues in tolerability in comparison with 
the prefilled syringe.
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